⚠️ Important Safety Information
Boxed Warning: Thyroid C-cell tumors have been observed in animal studies. Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Consult your healthcare provider about your risk.
What is Ozempic?
Ozempic (semaglutide) is a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. It is FDA-approved for two indications:
1. Type 2 Diabetes: To improve blood sugar control in adults with type 2 diabetes, in combination with diet and exercise.
2. Cardiovascular Risk Reduction: To reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease.
Not FDA-approved for weight loss. Wegovy (same active ingredient, higher dose) is the FDA-approved formulation for chronic weight management.
New in 2026: Ozempic now also comes as a once-daily tablet (1.5 mg, 4 mg, and 9 mg) for adults with type 2 diabetes, available in the US since May 4, 2026 (Novo Nordisk, May 1, 2026; FDA label). For weight management, the FDA approved a 25 mg Wegovy pill on December 22, 2025 (Novo Nordisk) and a 7.2 mg Wegovy HD injection on March 19, 2026 (FDA).
How does Ozempic compare to other GLP-1 medications?
| Medication | Active Ingredient | Frequency | Average A1C Reduction | Average Weight Loss |
|---|---|---|---|---|
| Ozempic | Semaglutide | Once weekly | 1.5% (2 mg dose) | 12-14 lbs |
| Mounjaro | Tirzepatide | Once weekly | 2.0-2.5% (15 mg dose) | 15-25 lbs |
| Trulicity | Dulaglutide | Once weekly | 1.0-1.5% | 4-8 lbs |
| Victoza | Liraglutide | Daily | 1.0-1.5% | 6-10 lbs |
Data from respective FDA labels and head-to-head clinical trials. Individual results vary.
How does Ozempic work?
Semaglutide is a GLP-1 receptor agonist that works through three primary mechanisms:
1. Increases insulin secretion: Stimulates the pancreas to release insulin in response to elevated blood sugar (glucose-dependent, so lower risk of hypoglycemia when used alone).
2. Decreases glucagon secretion: Reduces the release of glucagon, a hormone that raises blood sugar, helping prevent glucose spikes.
3. Slows gastric emptying: Delays the movement of food from the stomach to the intestines, which slows the absorption of glucose and increases feelings of fullness.
These combined effects result in improved blood sugar control and, as a side effect, weight loss.
What do the clinical trials show?
Ozempic has been studied in the SUSTAIN clinical trial program involving over 8,000 patients with type 2 diabetes:
SUSTAIN 6 (Cardiovascular Outcomes): Demonstrated a 26% reduction in major adverse cardiovascular events (MACE) including cardiovascular death, nonfatal heart attack, and nonfatal stroke compared to placebo. Published in New England Journal of Medicine, 2016.
SUSTAIN 1-5 & 7 (Glycemic Control): Showed A1C reductions ranging from 1.0% to 1.8% depending on dose and baseline A1C. Weight loss ranged from 8-14 pounds on average over 30-56 weeks.
Common finding: Most patients experience nausea in the first 4-8 weeks, which typically improves over time. Gradual dose escalation helps minimize gastrointestinal side effects.
What should I discuss with my doctor?
Ozempic is a prescription medication that requires medical supervision. Before starting, discuss:
- Your complete medical history, especially any history of pancreatitis, kidney disease, diabetic retinopathy, or thyroid cancer
- All medications you're taking, especially insulin or sulfonylureas (increased hypoglycemia risk when combined)
- Whether you're pregnant, planning to become pregnant, or breastfeeding
- Your insurance coverage and whether you qualify for manufacturer savings programs
- Realistic expectations for blood sugar control and weight loss
This is not medical advice. Only your healthcare provider can determine if Ozempic is appropriate for you.
Frequently asked questions
Is Ozempic approved for weight loss?
Ozempic is FDA-approved only for type 2 diabetes, not for weight loss. However, a higher-dose formulation of the same active ingredient (semaglutide) is marketed as Wegovy and is FDA-approved specifically for chronic weight management. While Ozempic can cause weight loss as a side effect (average 12-14 pounds in clinical trials), using it off-label for weight loss should only be done under medical supervision.
How much does Ozempic cost?
Without insurance, Ozempic typically costs $900-$1,000 per month. With insurance, copays vary widely from $25 to $300+ depending on your plan. Novo Nordisk offers a savings card that may reduce copays to $25 for up to 24 months for eligible commercially insured patients. Medicare and Medicaid coverage varies by plan and state. Self-pay patients can pay less through NovoCare Pharmacy: $199 per month for the first two fills of 0.25 mg or 0.5 mg (new patients, through December 31, 2026), then $349 per month for 0.25 mg to 1 mg, and $499 per month for 2 mg. TrumpRx.gov lists the same $199 starting price.
What are the most common side effects?
The most common side effects are gastrointestinal: nausea (15-20% of patients), diarrhea (9%), vomiting (9%), constipation (5%), and abdominal pain (6%). These typically improve over time. Serious but rare risks include pancreatitis, gallbladder problems, kidney injury, diabetic retinopathy complications, and thyroid tumors (seen in animal studies, not yet confirmed in humans).